Liquid Biopsy Market 2017 Product Type, Market price,
Production Area , Analysis by Regions, Development
Trend, Manufacturing Base Distribution, and Forecast to
2025
A liquid biopsy is a simple and non-invasive technique that enables to discover a range of
information about a tumor through a simple blood sample. Some of the commercially available
liquid biopsy tests for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and
Target Selector liquid biopsy assays. A liquid biopsy test can detect epidermal growth factor
receptor (EGFR) gene mutations, evident in non-small cell lung cancer (NSCLC). The process
requires only 5 milliliters of blood and is quicker than a surgical biopsy. The blood sample is
processed to get 2 milliliters of plasma that is analyzed for tumor DNA. Potential of liquid
biopsies to detect disease progression or treatment resistance long before it would trigger
clinical symptoms or appear on imaging scans is major factor driving growth of liquid biopsy
market.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1223
Market Dynamics:
Factors such as rising prevalence of various cancers, rising demand for minimally invasive
procedures, and advantages offered by liquid biopsy over conventional tissue biopsy are
supporting growth of the liquid biopsy market. Liquid biopsy offers advantages over
conventional tissue biopsy such as early disease detection, real-time monitoring of the
metastasis and actual treatment response, detection of primary tumors and metastasis through
simple and non-invasive tests, and may be cheaper than conventional biopsy. Furthermore,
prevalence of various cancers is increasing and according to National Cancer Institute, 2016, an
estimated 16.8 million new cases of cancer are diagnosed in the U.S., with an around 595,690
deaths from the disease. The number of people with cancer is expected to rise to 19 million by
2024, indicating need for early disease diagnosis and treatment. Demand for minimally invasive
treatments is also increasing as tissue biopsy is an invasive approach for cancer diagnosis,
wherein, liquid biopsy is more convenient, which is expected to boost growth of the liquid
biopsy market.